Literature DB >> 26244774

Socioeconomic Status, Sex, Age and Access to Medications for COPD in Ontario, Canada.

Andrea Gershon1,2,3,4, Michael A Campitelli1, Jeremiah Hwee1, Ruth Croxford1, Teresa To1,3,4, Matthew B Stanbrook1,4, Ross Upshur1,2,4, Anne Stephenson1, Thérèse A Stukel1.   

Abstract

Disparities in COPD health outcomes have been found with older individuals, men and those of lower socioeconomic status doing worse. We sought to determine if this was due to differences in access to COPD medications. We conducted a retrospective cohort study using population health administrative data from Ontario, Canada, a province with universal prescription drug coverage for older adults. All individuals with COPD aged 67 years and older in 2008 who were not taking inhaled long-acting bronchodilators or inhaled corticosteroids were followed for 2 years. Poisson regression was used to determine the effects of age, sex, and socioeconomic status on the likelihood of initiating one of these medications, after adjusting for potential confounders. Over the study period, 54,050 of 185,698 (29.1%) older individuals with COPD not previously taking any inhaled long-acting bronchodilators or corticosteroids were initiated on one or more of these medications. After adjustment, individuals of low socioeconomic status, measured using neighborhood income level quintiles, were slightly more likely to initiate COPD medications than those of high socioeconomic status (relative risk (RR) 1.05; 95% confidence interval (95% CI) 1.02-1.08). While men received COPD medication at a consistent rate across all age groups, the likelihood that a woman received medication decreased with increasing age. With the exception of older women, there was minimal disparity in prescription for COPD medications. Disparity in health outcomes among Ontario COPD patients is not clearly explained by differences in medication access by socioeconomic status, sex or age.

Entities:  

Keywords:  community health; drug coverage; health inequity; population health

Mesh:

Substances:

Year:  2015        PMID: 26244774     DOI: 10.3109/15412555.2015.1020148

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  3 in total

1.  Trends in non-receipt of recommended COPD medication.

Authors:  Michael Poon; Priscila Pequeno; Shawn D Aaron; Matthew B Stanbrook; Harvey H Wong; Peter Cram; Andrea S Gershon
Journal:  ERJ Open Res       Date:  2022-04-25

2.  Identification of novel differentially methylated sites with potential as clinical predictors of impaired respiratory function and COPD.

Authors:  Mairead L Bermingham; Rosie M Walker; Riccardo E Marioni; Stewart W Morris; Konrad Rawlik; Yanni Zeng; Archie Campbell; Paul Redmond; Heather C Whalley; Mark J Adams; Caroline Hayward; Ian J Deary; David J Porteous; Andrew M McIntosh; Kathryn L Evans
Journal:  EBioMedicine       Date:  2019-03-29       Impact factor: 8.143

3.  Factors Associated With Nonreceipt of Recommended COPD Medications: A Population Study.

Authors:  Andrea S Gershon; Priscila Pequeno; Amanda Alberga Machado; Shawn D Aaron; Tetyana Kendzerska; Jin Luo; Matthew B Stanbrook; Wan C Tan; Joan Porter; Teresa To
Journal:  Chest       Date:  2021-06-16       Impact factor: 9.410

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.